Joel Gelfand

Credentials: · · ·

History

Risk of myocardial infarction in patients with psoriasis
JAMA · 2006 · First of 6 authors · Corresponding · 1,502 citations
Psoriasis and comorbid diseases: Epidemiology
Review · Journal of the American Academy of Dermatology · 2017 · Last of 7 authors · 904 citations
Prevalence of cardiovascular risk factors in patients with psoriasis
Journal of the American Academy of Dermatology · 2006 · Last of 6 authors · 772 citations

Psoriasis and the Risk of Diabetes
National Institute of Arthritis and Musculoskeletal and Skin Diseases · K24
Contact PI · $869.6K · University of Pennsylvania
2013–2018
A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease
National Heart, Lung, and Blood Institute · R01
Contact PI · $3.8M · University of Pennsylvania
2012–2017
Phase 1 Study of Resiquimod Gel Therapy for Cutaneous T-Cell Lymphoma
Food and Drug Administration · R01
PI · $395.2K · University of Pennsylvania
2012–2015
The Risk of Myocardial Infarction in Patients with Psoriasis
National Heart, Lung, and Blood Institute · R01
Contact PI · $3.8M · University of Pennsylvania
2009–2015

Light Treatment Effectiveness (LITE) Study
Principal investigator · Completed
University of Pennsylvania
2019–2023
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
Principal investigator · Completed · Phase 4
University of Pennsylvania
2014–2018
Vascular Inflammation in Psoriasis - Extension Study
Principal investigator · Completed · Phase 4
University of Pennsylvania
2013–2016
Vascular Inflammation in Psoriasis Trial (The VIP Trial)
Principal investigator · Completed · Phase 4
University of Pennsylvania
2012–2016